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Abstract
Background: Numerous gene loci are related to single measures of body weight and shape. We investigated if 55 SNPs
previously associated with BMI or waist measures, modify the effects of fat intake on weight loss and waist reduction under
energy restriction.
Methods and Findings: Randomized controlled trial of 771 obese adults. (Registration: ISRCTN25867281.) One SNP was
selected for replication in another weight loss intervention study of 934 obese adults. The original trial was a 10-week
600 kcal/d energy-deficient diet with energy percentage from fat (fat%) in range of 20–25 or 40–45. The replication study
used an 8-weeks diet of 880 kcal/d and 20 fat%; change in fat% intake was used for estimation of interaction effects. The
main outcomes were intervention weight loss and waist reduction. In the trial, mean change in fat% intake was 212/+4 in
the low/high-fat groups. In the replication study, it was 223/212 among those reducing fat% more/less than the median.
TFAP2B-rs987237 genotype AA was associated with 1.0 kg (95% CI, 0.4; 1.6) greater weight loss on the low-fat, and GG
genotype with 2.6 kg (1.1; 4.1) greater weight loss on the high-fat (interaction p-value; p = 0.00007). The replication study
showed a similar (non-significant) interaction pattern. Waist reduction results generally were similar. Study-strengths include
(i) the discovery study randomised trial design combined with the replication opportunity (ii) the strict dietary intake control
in both studies (iii) the large sample sizes of both studies. Limitations are (i) the low minor allele frequency of the TFAP2B
polymorphism, making it hard to investigate non-additive genetic effects (ii) the different interventions preventing identical
replication-discovery study designs (iii) some missing data for non-completers and dietary intake. No adverse effects/
outcomes or side-effects were observed.
Conclusions: Under energy restriction, TFAP2B may modify the effect of dietary fat intake on weight loss and waist
reduction.
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Introduction
Large genome-wide association studies (GWAS) have identified
32 gene loci in which single nucleotide polymorphisms (SNPs) are
robustly, though moderately, related to body mass index (BMI)
[1], and fewer variants have been related to proxy measures of
abdominal obesity [2–4]. All these genetic variants have been
related to body size measured at a single time point in adulthood.
Individuals differ greatly in weight loss response to energy
restriction [5–10]. A large part of the variation is likely explained
by variation in adherence to a prescribed diet [9], but differences
in physical activity and metabolic response determining energy
efficiency may also play a role. Twin studies indicate that genetic
predisposition influence weight change response during under-
feeding and overfeeding [11–13], but few studies have shown
effects of various genotypes on weight loss response [14–20].
The optimal macronutrient composition of a diet for weight loss
has been much debated [21,22]. We hypothesize that the individual
genetic background may influence which diet is the most effective
for weight loss. We previously investigated gene-macronutrient
interactions in the NUGENOB (Nutrient-Gene Interactions in
Human Obesity) study, in which obese men and women were
randomized to a 10-weeks hypocaloric diet with low or high fat
relative to carbohydrate content. The assigned diets showed similar
effects on weight loss [10], but we found that a SNP (rs7903146) of
the TCF7L2 gene associated with diabetes modified the effect of
randomized diet on weight loss [16]. However, we found no effect of
the obesity-associated SNP of the FTO gene on weight loss [15], or,
for the time, SNPs in a range of relevant candidate genes in obesity
[23] on the diet-weight loss association.
The aim of this study was to examine the effect of SNPs in gene
loci with an established association with body size or waist
measures, on changes in weight and waist circumference. In
NUGENOB we investigated main genetic effects and interactions
between SNPs in these gene loci and the randomized low- versus
high-fat group, and also for reported changes in energy intake
from fat and in total, in relation to weight loss and waist reduction.
In order to strengthen or refute findings of strong effects in
NUGENOB, we aimed at replication in another weight loss study
(Diet, Obesity and Genes, DiOGenes [24]).
Participants and Methods
NUGENOB
Information on the NUGENOB trial (http://www.nugenob.
com) has been previously described in detail [10]. Briefly, 771
obese men and women recruited to one of eight European centers
were randomly assigned to a low- or high-fat diet with
corresponding high or low carbohydrate content for ten weeks.
Inclusion criteria were a BMI of at least 30 kg/m2, and age 20–50
years. Participants were not included if they had experienced a
weight change more than 3 kg within three months prior to the
study, or if they reported other pre-identified characteristics that
could influence the results. Dietary targets were an energy intake
of 20–25% from fat (fat%) in the low-fat group, and 40–45 fat% in
the high-fat group. Both groups were prescribed a protein intake of
15 energy percentages with no or minimal alcohol consumption,
and the goal for energy intake was a daily energy deficit of
approximately 600 kcal, calculated by (1.36resting energy expen-
diture)-600. Dieticians instructed participants individually about
how to reach the assigned diet, and also about how to weigh and
record food intake. Weighed food recordings were requested from
participants for one weekend day and two weekdays at baseline
and at week ten of the intervention, and for one weekday at week
two and five. The reported intake was analyzed locally on country-
specific food databases. Participants were asked to maintain their
usual physical activity during the intervention.
Participants underwent a standardised clinical examination,
including anthropometry, at their clinical center shortly before and
after the intervention. Participants were instructed to avoid
strenuous exercise and abstain from drinking alcohol three days
prior to the examination, and to fast overnight and void the
bladder before measurements. All variables of diet and anthro-
pometry were checked for unrealistic values and outliers, and such
values, two or less for each variable, were excluded.
Gene loci selection and genotyping
Gene loci included were those that had shown a consistent
association with BMI, waist circumference, or waist-hip ratio in
GWAS [1–4,25–35]. In total 55 SNPs were included in the study.
The FTO SNP was genotyped by Taqman allelic discrimination
(KBioScience, Herts, UK), with a 96.9% genotyping success rate
and a genotyping error rate of 0.27%. Genome-wide genotyping
on the Illumina 317 k quad chip carried out at IntegraGen, Evry,
France, covered another 23 SNPs in this study, with a 99.1%
genotyping success rate. The remaining 31 SNPs were genotyped
by KASPar SNP Genotyping (KBioscience, Hoddesdon, UK).
Success rate was above 97% and error rate was below 0.5% in 183
replicate samples. We used Fisher’s exact test to evaluate Hardy-
Weinberg equilibirium (HWE) for all SNPs.
Statistical analysis
Drop-out rates by genotypes were compared by Pearson chi-
square statistics. The baseline BMI of completers and non-
completers were compared by two-sample t-test.
We used linear regression to calculate main genotype effects,
and gene-diet interactions, in relation to changes in weight and
waist. The additive genetic effects and the sum of genotypes, each
encoded 0, 1, or 2, equivalent to the number of obesity risk-alleles,
were analyzed. Dietary factors investigated were the two
randomized groups, and reported change in fat% and energy
intake.
Individual change in dietary intake was calculated as the
difference between mean intake over three days at baseline, and
the intake over five days during the intervention, with equal weight
for intake at the first part versus end of intervention. Change in
weight and waist circumference corresponded to the difference
between levels at baseline and directly after the intervention. All
regression models included change in weight or waist as dependent
variable, and explanatory variables were genotype, baseline weight
or waist, sex, a product term for sex and baseline weight or waist,
age, and study center. Analyses of gene-diet interactions addition-
ally included a product term of genotype and the dietary factor of
interest and also the dietary factor as main effect. Genetic effects
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on weight change and waist change are denoted as effects on
weight loss and waist reduction.
All statistical tests were two-sided and were performed in Stata
9.2 (StataCorp, LP, College Station, 2007).
Replication in DiOGenes
The strongest effects observed in NUGENOB were replicated in
the DiOGenes study (www.diogenes-eu.org). The trial has been
described in detail [24]; briefly, DiOGenes is an intervention study of
obese adults undergoing two phases; an 8-weeks weight loss phase on a
low-calorie diet, and 6–12 months weight maintenance on one of five
diets. Data from the weight loss phase were used in the present study.
Participants were men and women with a BMI between 27 and
45 kg/m2, recruited to one of eight European centers. Exclusion
criteria were characteristics that could potentially influence the
results, such as more than 3 kg weight change within two months
prior to the study and medications or certain diseases. Participants
of the study recorded their baseline dietary intake during two
weekdays and one weekend day. Weighed food recordings were
applied with instructions and procedures similar to those in
NUGENOB. The 8-weeks weight loss intervention consisted of a
low-calorie Modifast diet (Nutrition et Sante´). Four items per day
were selected from various products, each containing 202–
218 kcal. Participants were also allowed a daily intake of 200 g
tomatoes, 125 g cucumber, and 50 g lettuce. The low-calorie diet
provided approximately 880 kcal/d with an energy-percent from
fat of 20%, 54% from carbohydrates, and 26% from protein.
Anthropometric measurements were standardized across the
study centers. Height was measured four weeks before the trial.
Weight and waist circumference were measured 1–3 weeks before
the trial and right after the intervention.
In total 934 participants started the weight loss trial in
DiOGenes, and 790 of those had their DNA genome-wide
genotyped; missing individuals were due to little or low-quality
DNA. Genotyping was performed on the Illumina 660 k quad
chip carried out at the Centre National de Ge´notypage (CNG),
Evry, France. Genotyping was successful in 785 (99.4%) individ-
uals. Quality control (duplicates, sex discrepancy, non-European,
etc.) reduced the number to 734 (93%) and TFAP2B rs987237 was
called for all.
Statistical analysis was conducted as described for NUGENOB.
Dietary fat in gene-diet interaction analyses was in DiOGenes
assessed for change in fat% intake, calculated as the difference
between reported baseline intake and the common (approximate)
fat proportion of the intervention diet. The inter-individual
variation for calculated fat% change was therefore exclusively
determined by baseline dietary intake. Median fat% change was
used as cut-point for two groups of fat% change, which replaced
the randomized fat groups in NUGENOB. Statistical models were
identical in all other aspects.
Ethical considerations
The NUGENOB and DiOGenes trials have obtained written
informed consent from all study participants, and ethical approval
from the ethical committee at each study center. The names of the
local ethics committees were: (NuGenOb trial) Research Ethics
Committee of the University of Navarra, Spain; The Danish
Research Ethics Committee System, Denmark; Medical Ethics
Committee of the Maastricht University, Netherlands; Ethics
Committee of the Hoˆtel-Dieu Hospital, France; University of
Nottingham Medical School Ethics Committee, United Kingdom;
The Swedish National Council on Medical Ethics, Sweden; Ethics
Commission of the Medical School of Toulouse, France.
(DiOGenes trial) Research Ethic Committee of the University of
Navarra, Spain; The Danish Research Ethics Committee System,
Denmark; Medical Ethics Committee of the Maastricht Univer-
sity, Netherlands; Ethics Committee of the University of Potsdam,
Germany; Bedfordshire Local Research Ethics Committee, United
Kingdom;
Research Ethics Committee of the University of Crete, Greece;
Ethical Committee to the National Transport Multiprofile
Hospital in Sofia, Bulgaria; Ethical Committee of the Faculty
Hospital, Institute of Endocrinology, Prague, Czech Republic.
Results
NUGENOB
Out of 771 participants at start of the intervention, 648 (84%)
completed it (Figure 1). Completers and non-completers did not
differ significantly in baseline BMI (P=0.8). One weight gainer with
an extreme baseline BMI of 66 kg/m2 and five participants with
missing genotype data were excluded. For each of the 55 variants
included in the study, genotype data were available in 617–642
participants (95–99% of completers). Genotype distributions were
not related to drop-out rates except for ETV5 and FAIM2, which
hadmore completers among homozygotes than among non-carriers
of the obesity risk-allele (P=0.01 and 0.02 respectively), and for
PTBP2, which showed the opposite pattern (P=0.03). Of
completers with genotype data, 580 (90% of 642) participants had
dietary intake data available, and they were included in gene-diet
interaction analyses that included reported dietary intake.
Participants had a mean baseline BMI of 35.5 kg/m2, and mean
weight was 96.8 kg in women and 110.6 kg in men (Table 1).
Energy intake reduced by on average 615 kcal/d in the study group.
This was achieved by a reduction in absolute intake of macronu-
trients, with a greater decrease in fat intake in the low-fat group, and
a greater decrease of carbohydrates in the high-fat group. On
average, women lost 6.5 kg weight and 5.9 cm waist and men lost
7.9 kg weight and 7.7 cm waist during the intervention.
The distribution of genotypes, allele frequency, and outcome of
HWE test for the 55 gene loci are reported in Table S1. All minor
allele frequencies were larger than 0.05, and HWE tests were
acceptable with only one SNP (PFKP rs6602024) showing a P-
value below 0.01.
Table 2 shows P-values for main effects and interactions with
diet for 17 gene loci that reached nominal P-values below 0.05 for
an association with weight loss or waist reduction. The most
striking results were found for TFAP2B rs987237. This SNP
modified the effect on weight loss by fat group with a nominal P-
value for interaction of 0.00007, which also reached significance
after correction for multiple testing of 55 SNPs (0.05/55= 0.0009).
In an additive gene-diet interaction model, homozygotes for the A
allele lost 1.0 kg (95% confidence interval, CI, 0.4; 1.6) more
weight on the low-fat than on the high-fat diet, whereas
homozygotes for the G allele, i.e. the obesity risk-allele, lost
2.6 kg (95% CI, 1.1; 4.1) more weight on the high-fat diet
(Figure 2). A similar but weaker pattern was observed for waist
reduction (P for interaction= 0.03; Figure 3). TFAP2B was also
directly related to weight loss (P=0.04) with a 0.5 kg (95% CI, 0.0;
0.9) greater weight loss per G allele.
Three other gene loci showed P-values between 0.0003 and
,0.01 for a main effect or interaction with diet, in relation to
weight loss or waist reduction (Table S2). These were main effects
on weight loss by VEGFA, and a gene-fat group interaction in
relation to waist reduction for CTNNBL1 and NPC1.
The gene score (sum of all the risk alleles over genotypes)
showed no main effect or interaction with diet in relation to
outcomes (P$0.09).
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Table 1. Descriptive information with respect to the NUGENOB study.
Variable Women (n=481) Men (n=161) All (n=642)
Baseline Change* Baseline Change* Baseline Change*
Age, years 36.5 (7.9) 38.7 (7.6) 37.1 (7.9)
Weight, kg 96.8 (14.5) 26.5 (3.2) 110.6 (16.3) 27.9 (3.8) 100.3 (16.1) 26.8 (3.4)
BMI, kg/m2 35.8 (4.8) 22.4 (1.2) 34.7 (4.5) 22.5 (1.2) 35.5 (4.7) 22.4 (1.2)
Waist circumference, cm{ 103.2 (12.0) 25.9 (4.5) 113.9 (11.4) 27.7 (4.3) 105.9 (12.7) 26.3 (4.5)
Low-fat diet (n=298) High-fat diet (n=282) All (n=580)
Baseline Change{ Baseline Change{ Baseline Change{
Energy intake, kcal/d 2201 (691) 2652 (632) 2194 (625) 2576 (534) 2197 (659) 2615 (587)
Fat, E%1 36.7 (7.6) 211.6 (8.2) 37.0 (7.8) 3.9 (9.0) 36.9 (7.7) 24.1 (11.6)
Fat, g 90.9 (37.3) 247.4 (34.8) 91.2 (35.7) 217.5 (33.2) 91.1 (36.5) 232.9 (37.2)
Carbohydrates, E%1 45.2 (8.6) 11.5 (8.9) 44.8 (8.7) 22.9 (9.5) 45.0 (8.6) 4.5 (11.7)
Carbohydrates, g 246.7 (86.4) 227.2 (85.3) 245.0 (80.2) 275.8 (76.7) 245.9 (83.4) 250.9 (84.7)
Protein, E%1 16.3 (3.4) 1.6 (3.6) 16.3 (3.2) 0.7 (3.6) 16.3 (3.3) 1.2 (3.6)
Protein, g 87.7 (27.6) 218.7 (26.0) 88.4 (27.6) 219.7 (23.9) 88.1 (27.6) 219.2 (25.0)
Mean (SD) baseline level and change of body size by sex in 642 completers in NUGENOB with genotype data available, and dietary intake by randomized group in 580
completers with genotype data and dietary intake data available.
E%; percent of total energy intake.
*Difference between baseline and after the intervention.
{Data were missing in 14 participants.
{Difference between reported intake at baseline and during the intervention.
1Alcohol contributed with on average 1.8 E% (6.3 g) at baseline and the proportion reduced during the intervention.
doi:10.1371/journal.pone.0043212.t001
Figure 1. Participant flow in NUGENOB.
doi:10.1371/journal.pone.0043212.g001
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Replication of TFAP2B-fat interaction analyses in
DiOGenes
Out of 803 (86%) completers of the intervention, data on
TFAP2B were available in 639 participants, of which 590
participants had reported their dietary intake before the interven-
tion. Completers did not differ significantly from non-completers
with respect to BMI (P= 0.7) or TFAP2B genotype distribution
(P= 0.4).
Characteristics of DiOGenes participants are shown in Table 3.
Whereas the range for change in fat% intake in NUGENOB was
broad and largely related to randomized group, fat intake among
DiOGenes participants reduced much both in terms of absolute
intake (mean: 274.1 g/d, range: 2251.2 to 20.1 g) and fat%
Table 2. Regression results with respect to the NUGENOB study.









CTNNBL1 Weight 0.4 0.1 0.7 0.8
Waist 0.5 0.0003 0.05 0.2
FANCL Weight 0.2 0.6 0.8 0.03
Waist 0.5 0.5 0.9 0.9
GPRC5B Weight 0.2 0.1 0.046 0.2
Waist 0.4 0.5 0.5 0.6
LRRN6C Weight 0.3 0.01 0.1 0.5
Waist 0.9 0.02 0.4 0.9
MAF Weight 0.7 0.04 0.1 0.09
Waist 0.4 0.1 0.2 0.05
MAP2K5 Weight 0.9 1.0 0.3 0.9
Waist 0.4 0.7 0.9 0.03
MTIF3 Weight 0.1 0.4 0.3 0.6
Waist 0.04 0.8 0.5 0.7
NPC1 Weight 0.7 0.04 0.2 1.0
Waist 0.1 0.008 0.9 0.6
SLC39A8 Weight 0.7 0.4 0.8 0.9
Waist 0.3 0.2 0.03 0.7
ZNF608 Weight 0.06 0.6 0.9 0.1
Waist 0.01 0.5 0.6 0.7
MC4R Weight 0.09 0.3 0.4 0.049
Waist 0.5 0.9 0.9 0.2
TFAP2B Weight 0.04 0.00007 0.03 0.8
Waist 0.1 0.03 0.2 0.5
ADAMTS9 Weight 0.9 0.2 0.2 0.6
Waist 0.2 0.04 0.1 1.0
DNM3-PIGC Weight 0.8 0.6 0.2 0.02
Waist 0.3 0.3 0.8 0.2
LY86 Weight 0.02 0.4 0.6 0.2
Waist 0.1 0.7 0.7 0.3
RSPO3 Weight 0.3 0.1 0.5 0.01
Waist 0.3 0.045 0.2 0.3
VEGFA Weight 0.001 0.2 0.4 0.9
Waist 0.03 0.6 0.7 0.9
P-value for main genotype effect and interaction between genotype and diet in relation to weight loss and waist reduction for 17 gene loci with a P-value,0.05* for one
or more associations.
*P-values 0.01 to 0.05 are highlighted in italics and P-values,0.01 are highlighted in bold.
{See SNP information in Table S1.
{P-value for the additive effect of genotype adjusted for baseline weight or waist (weight/waist), sex, baseline weight/waist6sex, age, and center.
1P-value for the product term of genotype and the dietary factor of interest, adjusted for baseline weight/waist, sex, baseline weight/waist6sex, age, center, genotype,
and the dietary factor of interest.
IDifference between reported intake at baseline and during the intervention.
doi:10.1371/journal.pone.0043212.t002
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Figure 2. Weight loss over TFAP2B rs987237 genotypes in NUGENOB. Effect of randomized fat group (low-fat, LF, and high-fat, HF) on weight
loss in NUGENOB by TFAP2B rs987237. The y-axis displays the mean weight loss in each group. P-values for interaction, and effect estimates, were
derived from linear regression, based on the assumption of an additive genetic model.
doi:10.1371/journal.pone.0043212.g002
Figure 3. Waist reduction over TFAP2B rs987237 genotypes in NUGENOB. Effect of randomized fat group (low-fat, LF, and high-fat, HF) on
waist reduction in NUGENOB by TFAP2B rs987237. The y-axis displays the mean waist reduction in each group. P-values for interaction, and effect
estimates, were derived from linear regression, based on the assumption of an additive genetic model.
doi:10.1371/journal.pone.0043212.g003
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(mean: 217.3, range 243.7 to 1.7). The mean energy intake
reduction of 1351 kcal/d in DiOGenes was more than double the
reduction in NUGENOB, and weight loss and waist reduction was
greater.
Analysis of TFAP2B combined with a fat% reduction above or
lower than the median of 16.7 fat% showed similar patterns for
associations with weight loss (Figure 4) and waist reduction
(Figure 5) to those in NUGENOB, but statistical evidence for
interaction was weak (P=0.4). There were no main effects of
TFAP2B on weight loss (P=0.8) or waist reduction (P=0.6).
Additional robustness analyses in NUGENOB and DiOGenes
of the TFAP2B-dietary fat interaction are described in supporting
material Text S1 and displayed in Table S3 and S4.
Discussion
In this study of weight loss in obese men and women on a 10-
weeks energy restricted diet low or high in fat to carbohydrate
content, we investigated main effects and gene-diet interactions of
55 gene loci with an established association with BMI or waist
measures at genome-wide significant levels. We found that the
TFAP2B gene locus rs987237 clearly modified the effect of a high
versus low-fat diet on weight loss. Whilst non-carriers of the
obesity risk-allele lost more weight on the low-fat diet, the opposite
was shown among homozygotes of the obesity risk-allele. These
results showed a similar, though non-significant, pattern in another
weight loss study of a low-calorie diet for eight weeks when
comparing participants with a small versus large reduction of fat%
intake. The similar pattern of results from these different studies
indicates that under energy restriction, TFAP2B may influence the
effect of dietary fat on weight loss.
Several factors may underlie the much weaker associations
observed in the replicated analysis. Analyses in NUGENOB were
performed in line with the original design; two randomized groups
of low or high fat% intake were compared. Besides the control of
unknown confounders owing to randomization, the two groups in
NUGENOB were also more diverse in their changed fat% intake
than were the constructed groups in DiOGenes with different
decreases in dietary fat% intake. Moreover, we lacked information
on the actual individual dietary intake during the intervention in
DiOGenes, so dietary change calculations assumed complete
adherence to the prescribed diet and this assumption is likely not
to be entirely met. Given these limitations to enable replication of
the findings in NUGENOB, the similar pattern observed in
DiOGenes is quite noteworthy. Many of the same limitations in
DiOGenes confer also to NUGENOB for investigation of change
in fat% and energy intake. Misclassification of self-reported dietary
intake, small variation in exposure or small differences between
compared groups, and confounding issues may have obscured the
finding of further strong gene-diet interactions in NUGENOB,
and a clearer replication of TFAP2B-dietary fat interaction in
DiOGenes.
Other limitations of the study are the incomplete data due to
drop-outs of study participants, and incomplete genotyping and
dietary intake reports. Around 15% of study participants did not
complete the trials; however, completers and non-completers did
neither differ in baseline BMI nor in overall genotype distribution.
Dietary intake data were incomplete in both studies, but were
based on weighed food records over several days that, despite its
Table 3. Descriptive information with respect to the DiOGenes study.
Variable Women (n=415) Men (n=224) All (n=639)
Baseline Change* Baseline Change* Baseline Change*
Age, years 41.0 (6.3) 43.0 (5.5) 42.0 (6.1)
Weight, kg 94.9 (15.4) 29.9 (3.0) 109.5 (17.3) 212.8 (4.1) 100.0 (17.5) 210.9 (3.7)
BMI, kg/m2 34.5 (4.9) 23.7 (1.0) 34.4 (4.6) 24.0 (1.2) 34.5 (4.8) 23.8 (1.1)
Waist circumference, cm{ 104.3 (11.8) 29.1 (4.7) 114.6 (12.4) 211.1 (4.3) 107.9 (13.0) 29.8 (4.7)
.16.7 fat% decrease(n=295) ,16.7 fat% decrease{(n=295) All (n=590)
Baseline Change1 Baseline Change1 Baseline Change1
Energy intake, kcal/d 2307 (774) 21427 (774) 2154 (778) 21274 (777) 2231 (779) 21351 (779)
Fat, E%I 43.5 (5.1) 223.0 (5.1) 32.0 (3.8) 211.6 (3.8) 37.8 (7.3) 217.3 (7.3)
Fat, g 111.1 (40.5) 291.1 (40.5) 77.4 (31.3) 257.4 (31.3) 94.1 (39.8) 274.1 (39.8)
Carbohydrates, E%I 38.0 (6.2) 15.7 (6.2) 47.6 (7.2) 6.0 (7.2) 42.8 (8.3) 10.8 (8.3)
Carbohydrates, g 218.1 (77.6) 2100.1(77.6) 257.2(100.3) 2139.2(100.3) 237.5(91.7) 2119.5(91.7)
Protein, E%I 17.1 (4.0) 8.8 (4.0) 17.0 (4.5) 8.9 (4.5) 17.1 (4.3) 8.8 (4.3)
Protein, g 96.5 (34.5) 239.5 (34.5) 88.3 (30.3) 231.3 (30.3) 92.4 (32.7) 235.4 (32.7)
Mean (SD) baseline level and change of body size by sex in 639 completers in DiOGenes in whom TFAP2B was successfully genotyped, and dietary intake in groups split
by median change in fat% intake in 590 completers with TFAP2B data and dietary intake data available.
E%; percent of total energy intake.
*Difference between baseline and after the intervention.
{Data were missing in 41 participants.
{One participant reported an increased (1.7 units) fat% intake.
1Difference between reported intake at baseline and the standardised low-calorie diet of 880 kcal/day, including macronutrients: fat, 20 g, 20 E%; carbohydrates, 118 g,
54 E%; and protein, 57 g, 26 E%.
IAlcohol contributed with on average 2.3 E% (7.9 g) at baseline and no alcohol was allowed during the intervention.
doi:10.1371/journal.pone.0043212.t003
TFAP2B Influences Dietary Fat-Weight Loss Effect
PLOS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e43212
Figure 4. Weight loss over TFAP2B rs987237 genotypes in DiOGenes. Effect of fat% reduction on weight loss in DiOGenes by TFAP2B rs987237.
The two groups of fat% reduction were divided by themedian reduction of 16.7 energy percent. The y-axis displays themean weight loss in each group.
P-values for interaction, and effect estimates, were derived from linear regression, based on the assumption of an additive genetic model.
doi:10.1371/journal.pone.0043212.g004
Figure 5. Waist reduction over TFAP2B rs987237 genotypes in DiOGenes. Effect of fat% reduction on waist reduction in DiOGenes by TFAP2B
rs987237. The two groups of fat% reduction were divided by the median reduction of 16.7 energy percent. The y-axis displays the mean waist reduction
in each group. P-values for interaction, and effect estimates, were derived from linear regression, based on the assumption of an additive genetic model.
doi:10.1371/journal.pone.0043212.g005
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weaknesses owing to self-report, is frequently used as gold standard
method for assessment of dietary intake [36].
The major strength of the study is the relatively large sample
size of two well-controlled intervention studies of similar partic-
ipant characteristics, allowing replication of analyses for highly
significant findings. Replication is crucial to avoid spurious chance
findings emerging from multiple testing. Although analyses in
DiOGenes did not replicate the strong findings in NUGENOB,
the patterns of results were consistent.
The TFAP2B gene has been associated with type 2 diabetes
[37], and was recently found to be related to BMI [1] and waist
circumference [4]. The TFAP2B gene encodes for a transcriptional
factor-activating enhancer-binding protein-2b (AP-2b) and is
preferentially expressed in adipose tissue [37]. Overexpression of
TFAP2B leads to increased glucose uptake and thereby triglyceride
accumulation and insulin resistance in adipocytes [38]. The
TFAP2B rs987237 variant investigated in this study, located in
intron 3, may not be the causal variant. It may, however, be a
marker of the enhancer activity, since it is in complete linkage
disequilibrium (r2 = 1) with an intronic enhancer variant that
influences TFAP2B expression in adipose tissue [39]. Yet, the
mechanisms whereby TFAP2B could modify the effect of dietary
fat intake on weight loss are unclear. It is also unclear whether
TFAP2B indeed interacts with dietary fat, as focused on in our
paper, or rather with carbohydrates, or the fat-carbohydrate ratio.
Speculatively, individuals of different TFAP2B genotype and gene
expression metabolise fat or other macronutrients differently, and
thus, respond differently to dietary change of macronutrient
composition.
In conclusion, this study of obese men and women showed a
clear interaction between TFAP2B and a diet low or high in fat, on
weight loss under energy restriction. A similar, but nonsignificant,
pattern for interaction between TFAP2B and dietary fat intake was
shown in another weight loss study of similar participant
characteristics. Results of our study strongly encourage further
examination of the role of TFAP2B and macronutrients in weight
loss.
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Figure S1 Weight loss over TFAP2B rs987237 genotypes
in NUGENOB based on general genetic model. Effect of
randomized fat group (low-fat, LF, and high-fat, HF) on weight
loss in NUGENOB by TFAP2B rs987237. The y-axis displays the
mean weight loss in each group. P-values for interaction, and effect
estimates, were derived from linear regression, based on the
assumption of a general genetic model (SNP coded as a categorical
variable).
(TIF)
Figure S2 Waist reduction over TFAP2B rs987237 geno-
types in NUGENOB based on general genetic model.
Effect of randomized fat group (low-fat, LF, and high-fat, HF) on
waist reduction in NUGENOB by TFAP2B rs987237. The y-axis
displays the mean waist reduction in each group. P-values for
interaction, and effect estimates, were derived from linear
regression, based on the assumption of a general genetic model
(SNP coded as a categorical variable).
(TIF)
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included in the study.
(PDF)
Table S2 Genes with interesting findings (P,0.01). Gene
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adjustments, in NUGENOB.
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Table S4 Sensitivity analysis for weight loss over
TFAP2B rs987237 genotypes in DiOGenes. P-value for
interaction between TFAP2B and fat group, and beta (95%
confidence interval) for fat group by TFAP2B variant, in relation
to weight loss, in analyses varying in fat group definition and
adjustments, in DiOGenes.
(PDF)
Text S1 Outline of sensitivity analysis for weight loss
over TFAP2B rs987237 genotypes. Includes descriptions of
both additional sensitivity analyses for the TFAP2B-dietary fat
interaction (results in Table S3 and S4) as well as of analyses
based on the general genetic model (SNP coded as a categorical
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